Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

metabolic · Mechanism Report

Does genetic variation in FMO3 influence circulating TMAO levels?

Common genetic variants in FMO3 alter its enzymatic capacity to oxidize trimethylamine (TMA) to TMAO and thereby change circulating TMAO levels.

PlausibleJuly 1, 202617 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Genetic variation in FMO3 can change enzymatic activity and thereby influence circulating trimethylamine N-oxide (TMAO) levels in humans.

laying out figure…
0 of 2 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim links missense variants (e.g., E158K, E308G) and certain haplotypes in FMO3 to reduced hepatic catalytic efficiency, which lowers the conversion rate of gut-derived TMA into TMAO and shifts the circulating TMA/TMAO balance. It also frames this genetic effect as a baseline determinant of systemic TMAO that operates alongside renal clearance, dietary intake, and gut microbiome composition.

Verified conclusion

The flavin-containing monooxygenase 3 (FMO3) enzyme plays a central role in human metabolic health, acting as the primary bridge between gut microbial metabolism and systemic cardiovascular physiology.

Genetic and clinical evidence

  • Polymorphic variation: Common genetic variants in the FMO3 gene, specifically the rs2266782 (E158K) and rs2266780 (E308G) missense mutations, significantly alter hepatic FMO3 protein abundance and metabolic efficiency. While individual variants may only moderately affect function, compound genotypes or specific haplotypes markedly decrease overall catalytic activity.
  • Clinical translation: In chronic heart failure cohorts, individuals with the rs2266782 (E158K) AA genotype exhibit significantly lower plasma TMAO levels than G-allele carriers, demonstrating how inherited genetic variations directly dictate systemic biomarker concentrations.

Mechanistic explanations

  • Hepatic oxidation pathway: Hepatic FMO3 is the rate-limiting enzyme responsible for converting over 90% of gut-microbiota-derived trimethylamine (TMA) into trimethylamine N-oxide (TMAO). Genetically altered FMO3 catalytic efficiency directly modulates this specific metabolic step, directly shifting the ratio of circulating TMA to oxidized TMAO.

Systemic and clinical implications

  • Cardiovascular association: Tracking these genetic and metabolic shifts is highly relevant, as elevated circulating TMAO levels are independently associated with an increased risk of major adverse cardiovascular events (MACE) and mortality.
  • Modulating factors: While FMO3 genetics establish baseline metabolic capacity, systemic TMAO levels are heavily co-determined by renal function—which is the primary route of systemic clearance—as well as dietary intake and gut microbiome composition.

Bottom line

  • Genetic variations in the FMO3 gene directly alter its enzymatic capacity to oxidize TMA into TMAO, establishing a clear genetic influence on circulating TMAO levels that operates alongside renal clearance and dietary inputs.

References

  1. In vivo variability of TMA oxidation is partially mediated by ... - PubMed — pubmed.ncbi.nlm.nih.gov ↗
  2. Polymorphisms of the Flavin containing monooxygenase 3 (FMO3 ... — pmc.ncbi.nlm.nih.gov ↗
  3. Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver — pmc.ncbi.nlm.nih.gov ↗
  4. Effects upon in vivo nicotine metabolism reveal functional variation ... — pmc.ncbi.nlm.nih.gov ↗
  5. [PDF] Trimethylamine-N-Oxide: Friend, Foe, or Simply Caught in the Cross ... — bevital.no ↗
  6. [PDF] A Novel Biomarker for the Identification of Inflammatory Bowel Disease — schulich.uwo.ca ↗
  7. Trimethylamine-N-Oxide, a Metabolite Associated with ... - PMC - NIH — pmc.ncbi.nlm.nih.gov ↗
  8. Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease — pmc.ncbi.nlm.nih.gov ↗
  9. FMO3--TMAO axis modulates the clinical outcome in chronic heart ... — journal.hep.com.cn ↗
  10. FMO3–TMAO axis modulates the clinical outcome in chronic heart ... — journal.hep.com.cn ↗
  11. Genetic Deficiency of Flavin-Containing Monooxygenase 3 ( Fmo3) Protects Against Thrombosis but Has Only a Minor Effect on Plasma Lipid Levels-Brief Report. — pmc.ncbi.nlm.nih.gov ↗
  12. Mutation, polymorphism and perspectives for the future of human ... — sciencedirect.com ↗
  13. Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease? — pmc.ncbi.nlm.nih.gov ↗
  14. Trimethylamine N-oxide (TMAO): From Gut Microbiome Pathway to ... — metwarebio.com ↗
  15. [PDF] Trimethylamine N-oxide is associated with long-term mortality risk — zehnatx.com ↗
  16. Trimethylamine N-oxide is associated with long-term mortality risk — pubmed.ncbi.nlm.nih.gov ↗
  17. Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible8 sourcesDoes the MTHFR rs1801131 A1298C variant mildly reduce enzyme activity and have a smaller homocysteine effect than C677T?→Plausible3 sourcesIs TMAO formed from gut microbial conversion of choline and carnitine followed by liver oxidation?→